METAVANT SCIENCES

Looking beyond the current treatment paradigms for metabolic disorders.

We are committed to developing innovative therapies for metabolic disorders.
Our current pipeline consists of two investigational drugs for the treatment of diabetes. Metabolic diseases represent one of the great public health challenges of our time. We see new opportunities on the horizon to improve the lives of patients with these conditions.

OUR PIPELINE

Imeglimin

Type 2 Diabetes with Chronic Kidney Disease 3b/4

 

LEARN MORE

RVT-1502

Type 1 Diabetes

 

LEARN MORE

OUR PARTNERS

Metavant Sciences has formed important alliances with companies who share our commitment to develop
innovative drug candidates into medicines that will change the lives of patients with cardiometabolic diseases.

ABOUT

DIABETES

Diabetes is one of the most pressing global health issues of the 21st century. In addition to the approximately 451 million adults who are estimated to have diabetes mellitus today, there are 318 million adults with impaired glucose tolerance, which puts them at significantly higher risk for developing the disease in the future.

Learn More